Published in Arthritis Rheum on October 01, 2008
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol (2012) 2.28
OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest (2011) 1.38
Osteoporosis in inflammatory joint diseases. Osteoporos Int (2010) 1.21
Osteoimmunology and osteoporosis. Arthritis Res Ther (2011) 1.20
Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. Endocrinology (2011) 1.01
Osteoclastogenesis and arthritis. Clin Exp Med (2010) 0.93
Osteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss. J Immunol Res (2015) 0.89
Osteoclast activators are elevated in intervertebral disks with Modic changes among patients operated for herniated nucleus pulposus. Eur Spine J (2015) 0.89
The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther (2012) 0.88
Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis Rheum (2011) 0.85
Collagen induces maturation of human monocyte-derived dendritic cells by signaling through osteoclast-associated receptor. J Immunol (2015) 0.81
A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts. Clin Rev Allergy Immunol (2016) 0.78
Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL. PLoS One (2016) 0.77
Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review. Clin Rev Allergy Immunol (2016) 0.76
Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol (2015) 0.76
Focal bone involvement in inflammatory arthritis: the role of IL17. Rheumatol Int (2015) 0.76
Structural basis of collagen recognition by human osteoclast-associated receptor and design of osteoclastogenesis inhibitors. Proc Natl Acad Sci U S A (2016) 0.76
IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1). J Biol Chem (2015) 0.76
Inflammatory diseases and bone fragility. Osteoporos Int (2017) 0.75
The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A (2011) 3.37
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol (2007) 2.82
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2012) 2.66
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med (2009) 2.55
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum (2010) 2.54
Adipocytokines in synovial fluid. JAMA (2003) 2.48
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol (2015) 2.39
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol (2014) 2.07
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity (2012) 2.06
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum (2004) 1.94
Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res (2004) 1.88
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Soluble RANKL and risk of nontraumatic fracture. JAMA (2004) 1.83
Detection of "Candidatus Neoehrlichia mikurensis" in two patients with severe febrile illnesses: evidence for a European sequence variant. J Clin Microbiol (2010) 1.82
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res (2010) 1.80
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol (2006) 1.74
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum (2008) 1.74
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum (2011) 1.71
The potential of adiponectin in driving arthritis. J Immunol (2006) 1.70
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med (2010) 1.67
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis (2010) 1.67
PPARβ/δ governs Wnt signaling and bone turnover. Nat Med (2013) 1.66
Joint protection and home hand exercises improve hand function in patients with hand osteoarthritis: a randomized controlled trial. Arthritis Rheum (2002) 1.65
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum (2007) 1.62
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor α-mediated experimental arthritis. Arthritis Rheum (2013) 1.59
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis (2007) 1.58
Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis (2012) 1.58
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis (2013) 1.57
Pachydermodactyly: a review. Curr Rheumatol Rep (2014) 1.56
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis (2011) 1.56
T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med (2014) 1.56
Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol (2005) 1.55
In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum (2004) 1.55